BQD(03866): The issuance of the Capital Bonds (First Tranche) with no fixed term in 2026 has been completed.
Qingdao Bank (03866) announced that with the approval of the Qingdao Regulatory Bureau of the China Banking and Insurance Regulatory Commission and the People's Bank of China, Qingdao Bank Co., Ltd. successfully issued the "Qingdao Bank Co., Ltd. 2026 Perpetual Capital Bonds (Series 1)" on the national interbank bond market in recent days.
BQD (03866) announced that, with the approval of the Qingdao Regulatory Bureau of the China Banking and Insurance Regulatory Commission and the People's Bank of China, BQD Limited (the Company) has successfully issued the "BQD Limited 2026 Perpetual Capital Bonds (First Tranche)" (this Bonds) in the national interbank bond market in recent days.
This Bond was registered on July 7, 2026, and was fully issued on July 9, 2026, with a total issuance size of 4 billion yuan. The coupon rate for the first 5 years of this Bond is 2.01%, adjusted every 5 years. The Company has the right to redeem all or part of this Bond on each interest payment date after the 5th year.
Related Articles
YNBY INTL (00030) spent 4.125 million Hong Kong dollars on July 9 to repurchase 15 million shares.
DONGYUE GROUP (00189) announces positive profit growth, with an expected increase of over 31% in net profit attributable to shareholders in the first half of the year compared to the same period last year.
The joint development of the Phase III clinical trial of the heart drug did not reach the primary endpoint, causing the stock prices of Astrazeneca PLC Sponsored ADR (AZN.US) and Ionis (IONS.US) to plummet.
YNBY INTL (00030) spent 4.125 million Hong Kong dollars on July 9 to repurchase 15 million shares.
DONGYUE GROUP (00189) announces positive profit growth, with an expected increase of over 31% in net profit attributable to shareholders in the first half of the year compared to the same period last year.
The joint development of the Phase III clinical trial of the heart drug did not reach the primary endpoint, causing the stock prices of Astrazeneca PLC Sponsored ADR (AZN.US) and Ionis (IONS.US) to plummet.
RECOMMEND
